Advances in Biopharmaceutical Formulation Strategies for Enhancing Oral Bioavailability of Poorly Water-Soluble Drugs

Dr. Rajesh K Sharma [1]*, Dr. Emily S Patel [2]
[1] Professor, PhD Centre for Advanced Drug Delivery Manipal College of Pharmaceutical Sciences, India
[2] Professor, PhD Division of Drug Delivery and Biomaterials University of Alberta, Canada

* Corresponding Author: **Dr. Rajesh K Sharma**

Article Info

ISSN (online): 3107-393X
Volume: 03
Issue: 02
Received: 07-01-2026
Accepted: 06-02-2026
Published: 05-03-2026
Page No: 15-21

Abstract
The oral route remains the preferred modality for chronic drug administration due to patient convenience and compliance; however, approximately 40% of approved drugs and 70% of new chemical entities exhibit poor aqueous solubility that limits gastrointestinal absorption and therapeutic efficacy. The Biopharmaceutics Classification System categorizes these compounds as Class II (low solubility, high permeability) and Class IV (low solubility, low permeability), presenting distinct formulation challenges requiring mechanistically designed delivery systems. This review examines contemporary biopharmaceutical strategies for enhancing oral bioavailability through solubility and dissolution rate improvement, with emphasis on the physicochemical principles governing each approach. Solid dispersions utilizing hydrophilic polymers achieve thermodynamic stabilization of amorphous drug forms, generating supersaturated solutions that drive absorption. Nanocrystal technologies exploit surface area-to-volume relationships through particle size reduction, enabling dissolution rates that overcome gastrointestinal transit limitations. Lipid-based formulations—including self-emulsifying drug delivery systems, nanoemulsions, and lipid nanoparticles—facilitate drug solubilization within the gastrointestinal milieu and exploit lymphatic transport pathways to bypass hepatic first-pass metabolism. Polymeric and lipid nanocarriers provide encapsulation matrices that control drug release while protecting against enzymatic degradation. Hybrid platforms incorporating mesoporous silica or cyclodextrin complexes combine multiple enhancement mechanisms for synergistic bioavailability improvement. *In vitro–in vivo* correlation utilizing bio relevant dissolution media enables predictive formulation development and regulatory acceptance. Comparative evaluation reveals trade-offs among stability, manufacturability, and enhancement magnitude that guide technology selection based on drug physicochemical properties and therapeutic requirements. Challenges including supersaturating maintenance, polymorphic transformation, and patient variability necessitate continued innovation toward personalized oral delivery systems integrating artificial intelligence-driven formulation design.

Keywords: Oral bioavailability; poorly water-soluble drugs; bio pharmaceutics; lipid-based systems; solid dispersions; nan crystals

1. Introduction

Oral drug administration constitutes the cornerstone of chronic pharmacotherapy, offering advantages in patient acceptance, treatment adherence, and healthcare economics [1]. Despite these benefits, the successful oral delivery of many therapeutic agents is compromised by inadequate aqueous solubility, which limits dissolution within gastrointestinal fluids and subsequent absorption across intestinal epithelia. The prevalence of this challenge has intensified with the evolution of drug discovery paradigms, wherein high-throughput screening and combinatorial chemistry increasingly generate lipophilic high-molecular-weight candidates with poor water solubility [2].

Current estimates indicate that approximately 40% of marketed drugs and up to 70% of new chemical entities exhibit solubility-limited absorption.

The Biopharmaceutics Classification System (BCS), established by Amidon and colleagues, provides a scientific framework for understanding and addressing these limitations [3]. The system categorizes drugs based on aqueous solubility and intestinal permeability into four classes: Class I (high solubility, high permeability), Class II (low solubility, high permeability), Class III (high solubility, low permeability), and Class IV (low solubility, low permeability). BCS Class II and IV compounds constitute the primary focus of solubility-enabling formulation technologies, as their oral absorption is limited by dissolution rate or solubility rather than membrane permeability [4].

Conventional formulation approaches—including simple tablet compression, capsule filling, or suspension preparation—prove inadequate for poorly water-soluble drugs, resulting in incomplete and variable absorption that compromises therapeutic efficacy and increases interpatient variability [5]. This limitation has driven intensive research into advanced formulation strategies that enhance apparent solubility, dissolution rate, and gastrointestinal residence time. These approaches leverage fundamental physicochemical principles including particle size reduction, solid-state manipulation, lipid-based solubilization, and nanoscale encapsulation.

This review provides a comprehensive examination of contemporary biopharmaceutical strategies for enhancing oral bioavailability of poorly water-soluble drugs. The mechanistic basis of each approach is analyzed, followed by evaluation of their relative advantages and limitations. Translational considerations including *in vitro–in vivo* correlation (IVIVC), manufacturability, and regulatory acceptance are addressed, with emphasis on clinical relevance and future directions.

2. Biopharmaceutical Barriers to Oral Bioavailability

2.1. Solubility and Dissolution Limitations

The dissolution of a solid drug in gastrointestinal fluids is governed by the Noyes–Whitney equation: $dC/dt = (D \times A \times (Cs - C))/h$, where dC/dt represents dissolution rate, D is diffusion coefficient, A is surface area available for dissolution, Cs is saturation solubility, C is concentration in bulk medium, and h is diffusion boundary layer thickness [6]. For poorly water-soluble drugs, low Cs values fundamentally limit the driving force for dissolution, while the hydrophobic nature of drug particles may also reduce effective surface area due to agglomeration and poor wetting.

The gastrointestinal environment imposes additional constraints, including limited fluid volume (250–500 mL), variable pH along the intestinal tract, and the presence of bile salts and dietary lipids that may enhance or inhibit solubilization [7]. The transit time through small intestine (3–4 hours) provides a finite window for dissolution and absorption, requiring rapid dissolution to achieve therapeutic concentrations before drug reaches poorly permeable colonic regions [8].

Supersaturation—the generation of drug concentrations exceeding equilibrium solubility—represents a transient state that can enhance absorption if maintained within the intestinal lumen [9]. However, supersaturated solutions are thermodynamically unstable and prone to precipitation, necessitating polymeric stabilizers that inhibit nucleation and crystal growth.

2.2. Permeability and Absorption Constraints

Following dissolution, drug molecules must traverse the intestinal epithelium through transcellular (passive diffusion, carrier-mediated transport) or paracellular pathways. BCS Class II drugs benefit from high intrinsic permeability, making dissolution the rate-limiting step, while Class IV compounds face dual barriers of poor solubility and limited permeability [10].

Efflux transporters, particularly P-glycoprotein (P-gp) localized on the apical membrane of enterocytes, actively transport substrate drugs back into the intestinal lumen, reducing net absorption [11]. Many lipophilic drugs are both poorly soluble and P-gp substrates, creating compounded bioavailability challenges. Formulation strategies that inhibit P-gp or bypass efflux transport through lymphatic uptake offer potential solutions.

2.3. First-Pass Metabolism and Stability Issues

Drugs absorbed from the gastrointestinal tract enter portal circulation and traverse the liver before reaching systemic circulation, exposing them to hepatic metabolism (first-pass effect). For extensively metabolized compounds, this can reduce oral bioavailability by 90% or more [12]. Additionally, enzymatic degradation within the intestinal lumen or epithelium—by cytochrome P450 enzymes, esterases, or peptidases—may further limit drug reaching the portal circulation.

Lymphatic transport offers an alternative absorption pathway that bypasses portal circulation and first-pass metabolism [13]. Lipophilic drugs with log P >5 and triglyceride solubility >50 mg/mL are preferentially incorporated into chylomicrons and transported via mesenteric lymphatics to systemic circulation, providing both bioavailability enhancement and reduced hepatic clearance.

3. Advanced Formulation Strategies for Solubility and Dissolution Enhancement

3.1. Solid Dispersions and Amorphous Systems

Solid dispersions comprise drug dispersed within an inert hydrophilic carrier matrix, typically a polymer, at solid state [14]. The drug may exist as amorphous domains, molecular dispersions, or crystalline particles depending on preparation method and drug–polymer interactions. Amorphous solid dispersions (ASDs) exploit the higher apparent solubility and dissolution rate of the amorphous form compared to crystalline counterparts, as amorphous materials lack the lattice energy required for crystal dissolution.

The mechanism of bioavailability enhancement involves generation and maintenance of supersaturated drug concentrations following dissolution. The polymer component serves multiple functions: stabilizing the amorphous drug during storage by inhibiting crystallization, providing hydrophilic character that enhances wetting and dissolution, and inhibiting precipitation from supersaturated solutions through interactions with drug molecules or crystal nuclei [15].

Key formulation considerations include polymer selection (polyvinylpyrrolidone, hydroxypropyl methylcellulose, Soluplus), drug–polymer miscibility, glass transition temperature, and manufacturing method (hot-melt extrusion, spray drying, freeze drying). Hot-melt extrusion offers

solvent-free processing and continuous manufacturing capability, while spray drying enables processing of heat-sensitive compounds [16].

3.2. Nanocrystals and Particle Size Reduction

Nanocrystal technology reduces drug particle size to the submicron range (100–1000 nm), dramatically increasing surface area available for dissolution according to the Noyes–Whitney relationship [17]. The increased surface area-to-volume ratio also increases saturation solubility according to the Ostwald–Freundlich equation, providing dual enhancement mechanisms.

Production methods include wet media milling (nanocrystal suspensions), high-pressure homogenization, and controlled precipitation [18]. Wet media milling using pearl mills with zirconium oxide beads generates stable nanosuspensions that can be converted to solid dosage forms by spray drying or granulation. Stabilization against agglomeration and Ostwald ripening requires appropriate surfactants or polymeric stabilizers.

Nanocrystal formulations offer advantages including high drug loading (approaching 100%), applicability to drugs with high melting points, and avoidance of organic solvents. Commercial products including Rapamune (sirolimus), Emend (aprepitant), and Tricor (fenofibrate) demonstrate clinical viability of this approach [19].

3.3. Lipid-Based Drug Delivery Systems

Lipid-based formulations encompass diverse systems including simple oil solutions, self-emulsifying drug delivery systems (SEDDS), self-microemulsifying drug delivery systems (SMEDDS), and self-nanoemulsifying drug delivery systems (SNEDDS) [20]. These formulations comprise lipids, surfactants, and cosolvents that spontaneously form fine emulsions upon dispersion in gastrointestinal fluids, presenting drug in solubilized form ready for absorption.

The mechanisms of bioavailability enhancement include: maintaining drug in dissolved state throughout gastrointestinal transit, stimulating bile and pancreatic secretions that enhance solubilization, increasing membrane fluidity, inhibiting efflux transporters, and promoting lymphatic transport [21]. The lipid digestion process, involving pancreatic lipase and bile salts, generates colloidal structures (mixed micelles, vesicles) that maintain drug solubilization during absorption.

Formulation design requires systematic screening of lipid–surfactant–cosolvent combinations to achieve optimal drug loading, dispersion properties, and digestibility. The Lipid Formulation Classification System categorizes formulations based on composition and dispersion characteristics, guiding development and regulatory assessment [22].

4. Nanotechnology-Based Approaches

4.1. Polymeric Nanoparticles

Polymeric nanoparticles (100–1000 nm) encapsulate drugs within biodegradable polymer matrices, providing controlled release and protection from degradation [23]. Common polymers include poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), chitosan, and Eudragit derivatives. Drug loading occurs through encapsulation during nanoparticle formation (emulsification-solvent evaporation, nanoprecipitation) or adsorption onto preformed particles.

Bioavailability enhancement mechanisms include: protection from enzymatic degradation in gastrointestinal tract, mucoadhesion prolonging intestinal residence time, uptake via Peyer's patches and M cells, and controlled release maintaining supersaturated concentrations [24]. Surface modification with polyethylene glycol (PEGylation) reduces mucoadhesion but may enhance penetration through mucus layers.

4.2. Lipid Nanocarriers

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) combine advantages of lipid-based systems with nanoscale delivery [25]. SLNs comprise solid lipids (e.g., glyceryl monostearate, cetyl palmitate) that solidify at body temperature, providing sustained release and protection. NLCs incorporate liquid lipids within solid matrix, creating imperfections that increase drug loading and reduce drug expulsion during storage.

These systems enhance oral bioavailability through: lipid digestion pathways generating solubilizing mixed micelles, lymphatic transport, inhibition of efflux transporters, and enhanced permeability due to surfactant components [26]. The solid matrix provides stability during storage while enabling controlled drug release.

4.3. Hybrid and Emerging Platforms

Mesoporous silica nanoparticles (MSNs) feature high surface area (up to 1000 m^2/g) and ordered pore structures (2–50 nm) that accommodate drug molecules in confined spaces [27]. Drug loading into mesopores inhibits crystallization, maintaining amorphous or molecularly dispersed states. The rigid silica matrix provides physical stability and enables functionalization for targeted or sustained release.

Cyclodextrin complexes utilize cyclic oligosaccharides with hydrophobic cavities that form inclusion complexes with poorly soluble drugs [28]. Complexation increases apparent solubility without requiring solid-state manipulation and can protect labile drugs from degradation. Hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin are widely used in approved products.

Prodrug approaches involve chemical modification of drug molecules with promoteties that enhance solubility or permeability, followed by enzymatic or chemical conversion to active drug after absorption [29]. Phosphate esters, amino acid esters, and lipid conjugates exemplify prodrug strategies that address both solubility and permeability limitations.

5. *In vitro–In vivo* Correlation and Translational Considerations

Predictive *in vitro* dissolution testing is essential for formulation development and quality control, but conventional compendial media often fail to reflect gastrointestinal conditions [30]. Biorelevant dissolution media simulating fasted and fed state intestinal fluids—containing bile salts, phospholipids, and digestion products—provide improved IVIVC for solubility-enhanced formulations.

Two-stage dissolution testing, incorporating pH transition from gastric to intestinal conditions, captures precipitation behavior of supersaturated systems. Nonsink dissolution conditions, where drug concentration approaches or exceeds saturation, are particularly relevant for evaluating supersaturation maintenance and precipitation inhibition [31].

Regulatory acceptance of solubility-enabling formulations requires demonstration of bioequivalence for generic products or characterization of bioavailability enhancement for new drugs. The FDA has issued guidance on BCS-based

biowaivers, though solubility-enhanced formulations typically require *in vivo* pharmacokinetic studies to confirm performance [32].

6. Comparative Evaluation of Formulation Strategies

6.1. Solid Dispersions

Solid dispersions offer high enhancement potential for crystalline drugs by generating amorphous forms with apparent solubility increases of 10- to 1000-fold. Advantages include applicability to wide range of drugs, established manufacturing technologies, and compatibility with conventional solid dosage forms [33]. Limitations include physical instability (amorphous-to-crystalline transformation) during storage, moisture sensitivity, and potential for drug–polymer phase separation.

6.2. Nanocrystals

Nanocrystals provide maximum drug loading with minimal excipients, avoiding concerns about amorphous stability. The technology is applicable to drugs with high melting points and those resistant to amorphization. Limitations include potential for particle growth during storage, need for specialized manufacturing equipment, and challenges in achieving reproducible nanosuspension properties [19].

6.3. Lipid-Based Systems

Lipid-based formulations excel for highly lipophilic drugs (log P >4) and those undergoing extensive first-pass metabolism. The dynamic digestion and absorption processes provide multiple enhancement mechanisms. Limitations include formulation complexity, potential for drug precipitation during digestion, stability issues with unsaturated lipids, and requirement for soft gelatin capsule fill.

6.4. Polymeric Nanoparticles

Polymeric nanoparticles offer versatility in release control and potential for targeted delivery, but relatively low drug loading (typically <20%) limits practical dose administration. Manufacturing complexity and scale-up challenges have restricted clinical translation compared to simpler technologies [24].

7. Challenges and Future Perspectives

7.1. Supersaturation Maintenance

The success of amorphous and lipid-based formulations depends on maintaining supersaturation throughout intestinal transit. Current precipitation inhibitors identified empirically lack predictive understanding of structure–activity relationships. Rational design of polymeric inhibitors based on drug–polymer interaction parameters and nucleation kinetics represents an emerging research frontier [9].

7.2. Long-Term Stability

Physical instability of amorphous systems—crystallization, phase separation, and moisture-induced transformations—remains a primary concern for commercial development. Accelerated stability testing under controlled humidity and temperature, combined with spectroscopic monitoring of solid-state form, guides formulation optimization [15].

7.3. Patient Variability

Gastrointestinal physiology varies substantially among patients due to age, disease states, fed/fasted conditions, and concomitant medications. These factors influence the performance of solubility-enhanced formulations, potentially increasing rather than reducing interpatient variability [8]. Understanding formulation performance across diverse populations is essential for clinical translation.

7.4. Personalized Oral Drug Delivery

The convergence of formulation science with patient-specific factors opens opportunities for personalized oral delivery. Pediatric and geriatric populations, patients with gastrointestinal disorders, and those receiving polypharmacy may benefit from formulations tailored to their physiological status [2]. Emerging 3D printing technologies enable on-demand production of personalized dosage forms.

7.5. Integration of AI in Formulation Design

Artificial intelligence and machine learning are increasingly applied to predict drug–excipient compatibility, optimize formulation composition, and forecast *in vivo* performance [5]. Neural networks trained on formulation databases can identify patterns linking physicochemical properties to successful outcomes, accelerating development and reducing experimental burden.

8. Conclusion

The oral delivery of poorly water-soluble drugs represents a persistent challenge in pharmaceutical development that demands mechanistically designed formulation strategies. Solid dispersions, nanocrystals, lipid-based systems, and polymeric nanocarriers each offer distinct approaches to enhancing bioavailability through solubility and dissolution rate improvement. The selection among these technologies should be guided by drug physicochemical properties, desired pharmacokinetic profile, and practical considerations of manufacturability and stability. Solid dispersions excel for crystalline drugs amenable to amorphization, nanocrystals provide maximal drug loading with minimal excipients, lipid-based formulations offer unique advantages for highly lipophilic compounds, and polymeric nanoparticles enable controlled release functionality. The integration of biorelevant dissolution testing and predictive modeling supports rational formulation development and regulatory acceptance. Future advances in maintaining supersaturation, ensuring long-term stability, and addressing patient variability will further enhance clinical utility. The continued evolution of formulation science, augmented by artificial intelligence and personalized medicine approaches, holds promise for expanding the oral armamentarium of poorly water-soluble therapeutics and improving patient outcomes through reliable, consistent drug absorption.

9. Tables

Table 1: Biopharmaceutical Barriers Affecting Oral Bioavailability of Poorly Water-Soluble Drugs

Barrier	Mechanistic Basis	Impact on Bioavailability	Formulation Strategy to Overcome
Poor aqueous solubility	Low saturation solubility (Cs) limits dissolution driving force	Incomplete dissolution within intestinal transit time	Amorphization, particle size reduction, lipid solubilization
Slow dissolution rate	Limited surface area, poor wetting, hydrophobic surface	Reduced concentration at absorption site	Nanocrystals, surfactants, hydrophilic carriers
Supersaturation instability	Nucleation and crystal growth from supersaturated solutions	Precipitation before absorption	Polymeric precipitation inhibitors
Efflux transport	P-gp and BCRP-mediated active efflux to intestinal lumen	Reduced net absorption	Inhibitors, bypass via lymphatic transport
First-pass metabolism	Hepatic and intestinal enzymatic degradation	Reduced systemic availability	Lymphatic targeting, metabolic inhibition
Enzymatic degradation	Proteases, esterases in GI tract	Drug destruction before absorption	Encapsulation, prodrug approaches

Table 2: Formulation Technologies for Enhancing Solubility and Dissolution of BCS Class II and IV Drugs

Technology	Mechanism of Enhancement	Advantages	Limitations	Example Drugs
Solid dispersions	Amorphization, particle size reduction, improved wetting	High enhancement ratio, flexible processing	Physical instability, moisture sensitivity	Itraconazole, griseofulvin, tacrolimus
Nanocrystals	Increased surface area, enhanced saturation solubility	High drug loading, minimal excipients	Particle growth, manufacturing complexity	Fenofibrate, aprepitant, sirolimus
SEDDS/SMEDDS	Lipid solubilization, micellar incorporation, lymphatic uptake	Bypasses first-pass, rapid dispersion	Precipitation during digestion, capsule filling	Cyclosporine, ritonavir, saquinavir
Cyclodextrin complexes	Inclusion complex formation, increased apparent solubility	Stabilization, simple preparation	High molecular weight, regulatory limits	Itraconazole, voriconazole, prostaglandins
Mesoporous silica	Pore confinement inhibiting crystallization, high surface area	Physical stability, high loading	Complex manufacturing, limited scale-up	Indomethacin, ibuprofen, fenofibrate
Prodrugs	Improved solubility via ionizable/ polar promoteties	Covalent solution, targeted activation	Additional development steps	Fosamprenavir, estramustine

Table 3: Nanotechnology-Based Oral Drug Delivery Systems and Their Mechanisms of Bioavailability Enhancement

Nanocarrier Type	Drug Loading Mechanism	Release Mechanism	Bioavailability Improvement Strategy	Clinical Status
Polymeric nanoparticles (PLGA, chitosan)	Encapsulation in polymer matrix	Diffusion, polymer degradation	M cell uptake, mucoadhesion, protection from degradation	Clinical trials
Solid lipid nanoparticles	Lipid matrix incorporation	Diffusion, lipid digestion	Lymphatic transport, P-gp inhibition	Preclinical/clinical
Nanostructured lipid carriers	Matrix with liquid lipid domains	Diffusion, lipid digestion	Enhanced loading, lymphatic uptake	Preclinical
Nanocrystals	Crystalline drug with stabilizer	Dissolution from high surface area	Surface area-driven dissolution	Marketed products
Lipid-polymer hybrid nanoparticles	Core-shell with lipid shell/polymer core	Dual-phase release	Combined lipid/polymer advantages	Preclinical
Nanostructured lipid-polymer hybrids	Engineered composite systems	Multi-mechanistic	Synergistic enhancement	Research stage

Table 4: Comparative Assessment of Advanced Biopharmaceutical Formulation Strategies

Parameter	Solid Dispersions	Nanocrystals	Lipid-Based Systems	Polymeric Nanoparticles	Clinical Implications
Drug loading	Moderate (10-50%)	High (>80%)	Moderate (10-40%)	Low (5-20%)	High loading preferred for high-dose drugs
Enhancement ratio	10-1000×	5-50×	5-50×	5-30×	Magnitude guides technology selection
Physical stability	Challenge (crystallization)	Good (crystalline)	Moderate (lipid oxidation)	Good (polymer dependent)	Critical for shelf-life
Manufacturing complexity	Moderate (spray drying, HME)	Moderate (media milling)	Low (blending, filling)	High (multiple steps)	Affects cost and scalability
In vivo variability	Moderate	Low	Moderate (food effects)	Low-moderate	Impacts clinical performance
Regulatory acceptance	Multiple approvals	Multiple approvals	Established (softgels)	Limited approvals	Guides development timeline
Dose form flexibility	Tablets, capsules	Tablets, capsules	Soft/hard capsules	Capsules, granules	Patient acceptance
Suitability for high-dose drugs	Limited by polymer content	Excellent	Limited by lipid volume	Limited by loading	Critical for dose strength

References

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of *in vitro* drug product dissolution and *in vivo* bioavailability. Pharm Res. 1995;12(3):413-420.
2. Ku MS, Dulin W. A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-of-Concept. Pharm Dev Technol. 2012;17(3):285-302.
3. Lennernäs H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol. 2005;57(3):273-285.
4. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420(1):1-10.
5. He Y, Ho C, Yang D, Chen J, Orton E. Application of artificial intelligence in pharmaceutical development for poorly water-soluble drugs. AAPS PharmSciTech. 2024;25(3):45-58.
6. Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm. 2006;321(1-2):1-11.
7. Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C. Simulation of fasting gastric conditions and its importance for the *in vivo* dissolution of lipophilic compounds. Eur J Pharm Biopharm. 2005;60(3):413-417.
8. Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and *in vitro* testing. Mol Pharm. 2010;7(5):1388-1405.
9. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549-2572.
10. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J. 2009;11(4):740-746.
11. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res. 2003;48(4):347-359.
12. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11-23.
13. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702-716.
14. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60.
15. Newman A, Knipp G, Zografi G. Assessing the performance of amorphous solid dispersions. J Pharm Sci. 2012;101(4):1355-1377.
16. Repka MA, Shah S, Lu J, *et al*. Melt extrusion: process to product. Expert Opin Drug Deliv. 2012;9(1):105-125.
17. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.
18. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63(6):427-440.
19. Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-310.
20. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3-4):278-287.
21. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231-248.
22. Feeney OM, Crum MF, McEvoy CL, *et al*. 50 years of oral lipid-based formulations: provenance, progress and future perspectives. Adv Drug Deliv Rev. 2016;101:167-194.
23. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1-27.
24. Plapied L, Duhem N, des Rieux A, Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci. 2011;16(3):228-237.
25. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
26. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170-184.
27. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278-1287.
28. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62(11):1607-1621.
29. Rautio J, Kumpulainen H, Heimbach T, *et al*. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7(3):255-270.
30. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15(1):11-22.
31. Bevernage J, Brouwers J, Brewster ME, Augustijns P. Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues. Int J Pharm. 2013;453(1):25-35.
32. U.S. Food and Drug Administration. Waiver of *in vivo* bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for

industry. December 2017. Available from: https://www.fda.gov/media/70958/download.
33. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068-1075.

How to Cite This Article
Sharma RK, Patel ES. Advances in biopharmaceutical formulation strategies for enhancing oral bioavailability of poorly water-soluble drugs. International Journal of Pharma Insight Studies Review. 2026;3(2):15–21.